Physician profile
Dawn Balcom
NPI 1811366404
$2,055.13
in general payments reported to CMS, 2019-2025
13 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $134 · 2022: $442 · 2023: $537 · 2024: $555 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $344.44 | 2021-2025 | Cresemba |
| Abbvie INC. | $334.73 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $325.28 | 2022-2025 | Zerbaxa, Dificid, Capvaxive |
| Pfizer INC. | $242.29 | 2022-2025 | |
| Gilead Sciences, INC. | $238.77 | 2021-2024 | Veklury |
| Insmed, INC. | $201.20 | 2023-2025 | Arikayce |
| Shionogi INC | $140.14 | 2023-2025 | Fetroja |
| Melinta Therapeutics, LLC | $99.39 | 2022-2024 | Orbactiv, Kimyrsa, Vabomere |
| Paratek Pharmaceuticals, INC. | $41.73 | 2022-2024 | Nuzyra |
| Ferring Pharmaceuticals INC. | $35.70 | 2023-2024 | Rebyota |
| Aimmune Therapeutics, INC. | $23.02 | 2023 | |
| Oxford Immunotec USA INC | $15.32 | 2022 | |
| Csl Behring | $13.12 | 2023 | Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Balcom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.